An hypothesis on crustacean pigmentation metabolism:L-carnitine and nuclear hormone receptors as limiting factors

Astaxanthin (Axn) is the primary pigment molecule in crustaceans associated with quality, health and growth traits, leading to increased marketing value. Axn can be contained within the protein complex crustacyanin (CRCN) to produce an array of different shell colours, or esterified with fatty acids (FA) for storage but also contributing additional red colouration. l-Carnitine (LC) has a major role in FA oxidation and mitochondrial function optimization, which could influence the proportion of Axn complexed with FA or CRCN. Peroxisome proliferator activated receptors (PPARs) have important roles in FA and Axn uptake, and stored lipid oxidation affecting Axn homeostasis and storage in lipid bodies. Whether Axn could increase PPAR signalling and carnitine palmitoyl transferase activity, leading to induction of lipid metabolism, is not known in crustaceans. Several FA have been shown to preferentially form FA Axn-esters, including saturated fatty acids (SFA) such as C16:0 and C18:0, mono-unsaturated fatty acids (MUFA) such as C16:1 and C18:1, and poly-unsaturated fatty acids (PUFA) such as C20:4, C20:5, and C20:6. We hypothesize that manipulating the dietary ratios and inclusion of LC, Axn, and specific FA may be able to further improve pigment utilization, lipid metabolism, health, and growth in crustaceans.</p

The Impact of Carnitine on Dietary Fiber and Gut Bacteria Metabolism and Their Mutual Interaction in Monogastrics

Carnitine has vital roles in the endogenous metabolism of short chain fatty acids. It can protect and support gut microbial species, and some dietary fibers can reduce the available iron involved in the bioactivity of carnitine. There is also an antagonistic relationship between high microbial populations and carnitine bioavailability. This review shows the interactions between carnitine and gut microbial composition. It also elucidates the role of carnitine bacterial metabolism, mitochondrial function, fiber fermentability, and short chain fatty acids (SCFAs)

LC/MS analysis of mushrooms provided new insights into dietary management of diabetes mellitus in rats

Mushrooms possess antihyperglycemic effect on diabetic individuals due to their nonfibrous and fibrous bioactive compounds. This study aimed to reveal the effect of different types of mushrooms on plasma glucose level and gut microbiota composition in diabetic individuals. The effects of five different mushroom species (Ganoderma lucidum, GLM; Pleurotus ostreatus, POM; Pleurotus citrinopileatus, PCM; Lentinus edodes, LEM; or Hypsizigus marmoreus, HMM) on alloxan-induced diabetic rats were investigated in this study. The results indicated that LEM and HMM treatments showed lower plasma glucose levels. For the microbiota composition, ACE, Chao1, Shannon, and Simpson were significantly affected by PCM and LEM treatments (p &lt; .05), while ACE, Shannon, and Simpson indexes were affected by HMM treatment (p &lt; .01). Simpson index was affected in positive control (C+) and POM groups. All these four indices were lower in GLM treatment (p &lt; .05). Dietary supplementation of mushrooms reduced plasma glucose level directly through mushrooms' bioactive compounds (agmatine, sphingosine, pyridoxine, linolenic, and alanine) and indirectly through stachyose (oligosaccharide) and gut microbiota modulation. In conclusion, LEM and HMM can be used as food additives to improve plasma glucose level and gut microbiome composition in diabetic individuals